LGI1-antibody associated epilepsy successfully treated in the outpatient setting

[1]  M. Battaglini,et al.  MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice , 2020, Nature Reviews Neurology.

[2]  J. Britton,et al.  Randomized Placebo‐Controlled Trial of Intravenous Immunoglobulin in Autoimmune LGI1/CASPR2 Epilepsy , 2019, Annals of neurology.

[3]  P. Bollu,et al.  Rapidly progressive global cerebral atrophy in the setting of anti-LGI1 encephalitis , 2019, BMJ Case Reports.

[4]  C. V. van Donselaar,et al.  Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis , 2019, Neurology.

[5]  G. Widman,et al.  The importance of early immunotherapy in patients with faciobrachial dystonic seizures , 2017, Brain : a journal of neurology.

[6]  M. Symmonds,et al.  LGI1-antibody encephalitis is characterised by frequent, multifocal clinical and subclinical seizures , 2017, Seizure.

[7]  H. Siebner,et al.  Global brain atrophy and metabolic dysfunction in LGI1 encephalitis: A prospective multimodal MRI study , 2017, Journal of the Neurological Sciences.

[8]  S. Irani,et al.  Autoantibody-mediated diseases of the CNS: Structure, dysfunction and therapy , 2017, Neuropharmacology.

[9]  J. Britton,et al.  Antiepileptic drug therapy in patients with autoimmune epilepsy , 2017, Neurology: Neuroimmunology & Neuroinflammation.

[10]  B. Bettcher,et al.  Episodic bradycardia as neurocardiac prodrome to voltage-gated potassium channel complex/leucine-rich, glioma inactivated 1 antibody encephalitis. , 2014, JAMA neurology.

[11]  R. Rocamora,et al.  Pilomotor seizures: An autonomic semiology of limbic encephalitis? , 2014, Seizure.

[12]  B. Bettcher,et al.  Effect of rituximab in patients with leucine-rich, glioma-inactivated 1 antibody-associated encephalopathy. , 2014, JAMA neurology.

[13]  J. Schott,et al.  Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis , 2011, Annals of neurology.

[14]  A. Vincent,et al.  Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia , 2010, Brain : a journal of neurology.

[15]  S. Smith,et al.  IMMUNOTHERAPY-RESPONSIVE SEIZURE-LIKE EPISODES WITH POTASSIUM CHANNEL ANTIBODIES , 2008, Neurology.